

1 **Title: Effectiveness of vaccination against symptomatic and asymptomatic**  
2 **SARS-CoV-2 infection: a systematic review and meta-analysis**

3 Meggiolaro A.<sup>1</sup>, Sane Schepisi M.<sup>1</sup>, Nikolaidis G.<sup>2</sup>, Mipatrini D.<sup>1</sup>, Siddu A.<sup>1</sup>, Rezza G<sup>1</sup>.

4 **ABSTRACT**

5 **OBJECTIVE:** To assess the effectiveness of SARS-CoV-2 vaccines in terms of prevention of disease  
6 and transmission. The evaluation was narrowed to two mRNA vaccines and two modified  
7 adenovirus vectored vaccines.

8 **METHODS:** A frequentist random effects meta-analysis was carried out after data extraction. Risk  
9 of bias of the included studies was assessed using New-Castle-Ottawa Scale. The overall risk of  
10 SARS-CoV-2 infection confirmed by real time Polymerase Chain Reaction (PCR) was estimated in  
11 partially and fully vaccinated individuals. The effect size was expressed as Relative Risk (RR) and  
12 RRR (RR reduction) of SARS-CoV-2 infection after vaccination. Potential sources of heterogeneity  
13 were investigated through between-study heterogeneity analysis and subgroup meta-analysis.

14 **RESULTS:** The systematic review identified 27 studies eligible for the quantitative synthesis.  
15 Partially vaccinated individuals presented a RRR=73% (95%CI=59%-83%) for any positive SARS-  
16 CoV-2 PCR (RR=0.27) and a RRR=79% (95%CI=30%-93%) for symptomatic SARS-CoV-2 PCR  
17 (RR=0.21). Fully vaccinated individuals showed a RRR=94% (95%CI=88%-98%) for any SARS-CoV-2  
18 positive PCR (RR=0.06) compared to unvaccinated. According to the subgroup meta-analysis, full  
19 BNT162b2 vaccination protocol achieved a RRR=84%-94% against any SARS-CoV-2 positive PCR  
20 and a RRR=68%-84% against symptomatic positive PCR. The RR for any SARS-CoV-2 positive PCR  
21 remained higher within elderly groups aged  $\geq 69$  years (RR=0.12-0.15) compared to younger  
22 individuals (RR=0.05-0.12). The RR against B.1.351 infection approached 0.40 for any positive PCR  
23 and 0.36 for symptomatic SARS-COV-2 while the RR of any B.1.1.7 infection was 0.14.

24 **CONCLUSION:** The current licensed vaccines may be transmission blocking, especially after full  
25 vaccination protocol. Given the substantial heterogeneity, results should be interpreted with  
26 caution. Subgroups meta-analyses suggested that the risk of any SARS-CoV-2 infection may be  
27 higher for non-B.1.1.7 variants and individuals aged  $\geq 69$  years. Further data and longer follow-up  
28 are required to investigate additional sources of heterogeneity and the effectiveness of SARS-CoV-  
29 2 vaccination within population subgroups.

### **STRENGTHS**

- Real-world data suggest that the current licensed vaccines may be transmission blocking, in particular after full vaccination protocol.
- The risk of any SARS-CoV-2 infection either symptomatic or asymptomatic, may be higher for non-B.1.1.7 variants and individuals aged  $\geq 69$  years.

### **LIMITATIONS**

- Given the substantial heterogeneity encountered in this meta-analysis, results should be interpreted with caution
- Further evidence on the impact of SARS-CoV-2 variants are vital in order to monitor mutations associated with vaccine escape

30

## **31 INTRODUCTION**

32 Since December 2020, infections with SARS-CoV-2 and the respective disease, COVID-19  
33 (Coronavirus Disease 2019), have spread worldwide. On 11 March 2020, WHO declared the  
34 COVID-19 outbreak a pandemic. The Coronavirus disease 2019 (COVID-19) has represented a  
35 serious threat to public health reporting nearly 4,038,342 deaths and 186,821,815 confirmed cases  
36 globally. As of 5 July 2021, 3,114,766,865 vaccine doses have been administered.[1]

37 Coronaviruses (CoVs), including SARS-CoV, MERS-CoV, and SARSCoV-2, are positive-sense, single  
38 stranded RNA viruses with four structural proteins (S protein, envelope (E) protein, membrane (M)  
39 protein, and nucleocapsid (N) protein).[2] The spike protein of SARS-CoV-2 binds to ACE2  
40 receptors on target cells and acts as immunodominant antigen, eliciting both antibody and T-cell  
41 responses.[3]

42 Most COVID-19 candidate vaccines have been developed including mRNA, adenoviral vectored  
43 vaccines, inactivated virus, and adjuvanted.[4] During the COVID-19 pandemic, the European  
44 medicines Agency (EMA) has applied a conditional marketing authorisation for the fast-track  
45 approval of safe and effective COVID-19 vaccines in the EU. Initially, EMA has recommended three  
46 COVID-19 vaccines to prevent COVID-19: Comirnaty (BNT162b2), Vaxzevria (ChAdOx1/AZD1222),  
47 Moderna (mRNA-1273). On March 2021, EMA has further expanded the arsenal of COVID-19  
48 vaccines available to European member states with the COVID-19 vaccine Janssen (Ad26.COVS.2.S).  
49 Each licensed vaccine should meet rigorous standards for safety, efficacy and quality, hence,

50 despite the earlier market authorization, a comprehensive monitoring process is generated post-  
51 approval.[5]

52 The vaccines currently authorised in the EU have proven high efficacy in Phase III clinical trial –  
53 such as Moderna’s COVID-19 vaccine with 94.5% efficacy and Pfizer’s with 95% efficacy – and  
54 likewise, they are expected to be highly effective in the real world. The effort to measure vaccine  
55 effectiveness is crucial to encouraging the vaccine uptake and to improving vaccine technology.[6,  
56 7] While efficacy estimate, in terms of degree to which a vaccine prevents disease and/or  
57 transmission, is measured under ideal circumstances such as Controlled Randomized Trials (RCTs),  
58 effectiveness refers to an estimate of the vaccine performance in the real world. Effectiveness is  
59 generally measured through observational studies where participants are not randomly assigned  
60 to an intervention versus a control group.[8]

61 The COVID-19 vaccination campaign has offered different options and the vaccines’ effect is not  
62 necessarily equal.[9-12] The controversy on whether the vaccination is sufficient to prevent any  
63 SARS-CoV-2 infection or it merely converts infections from symptomatic to asymptomatic has  
64 remained unsolved. Asymptomatic infection following vaccination could still spread the virus and  
65 nosocomial COVID-19 infections have been seemingly persistent within health care workers  
66 (HCWs), despite the vaccination.[13]

67 The main objective of this study was to estimate the effectiveness of conditional market licensed  
68 COVID-19 vaccines in terms of prevention of disease and transmission. The vaccine effectiveness  
69 (VE) was measured as relative risk (RR) and relative risk reduction (RRR) of any SARS-CoV-2  
70 infection, confirmed by polymerase chain reaction (PCR) test, on partially and fully vaccinated  
71 individuals respect to unvaccinated individuals. The meta-analysis estimated the overall RR of  
72 asymptomatic and symptomatic SARS-CoV-2 infections after partial and full vaccination protocol.  
73 The evaluation was narrowed to two mRNA vaccines (Comirnaty and Moderna), a modified  
74 adenovirus vaccine (COVID-19 Vaccine AstraZeneca or Vaxzevria) and a recombinant human  
75 adenovirus vector (Ad26.COVS.2 or Janssen or J&J).

76 Worldwide mass vaccination requires evidence synthesis on SARS-CoV-2 VE in order to drive  
77 health policy strategies. In particular, VE findings may address policy makers’ choices over  
78 mitigation measures following mass vaccination campaign, vaccine supply and deployment,  
79 vaccination protocol implementation.

## 80 **METHODS**

### 81 **Protocol registration**

82 The systematic review was prospectively registered on PROSPERO (n. CRD42021240143).

### 83 **Systematic Review**

84 The systematic review started on March 2021 and was concluded on May 15 2021. The main  
85 purpose of this research was to assess the risk of COVID-19 occurrence (any positive RT-PCR test)  
86 among vaccinated subjects. Moreover, we aimed at quantifying the risk of developing a  
87 symptomatic COVID-19 after vaccination. The evaluation was narrowed to BNT162b2, mRNA-  
88 1273, ChAdOx1/AZD1222 and Ad26.COV2.S vaccines. This research followed the PRISMA 2020  
89 statement.[14]

90 The search strategy was presented in details in Annex 1. We used seven different web engines,  
91 including early stage research platforms: Pubmed, Cochrane, clinicaltrial.gov, and COVID-NMA,  
92 medRxiv, SSRN, and Authorea. No restriction on language, setting or publication date was  
93 imposed.

94 The papers were selected initially by titles and abstracts. The full texts suitable for the quantitative  
95 synthesis were collected in an excel database for the data extraction. The exclusion criteria  
96 included lack of suitable data, and study design. We narrowed the quantitative synthesis to non-  
97 experimental studies only.

### 98 **Data extraction**

99 The data extraction was performed by two authors, independently. The results of the respective  
100 phase III RCTs were used as reference for data extraction.[6, 7, 15, 16] The information derived  
101 from each full text was classified into four categories of information: 1) outcome, 2) study  
102 characteristics (design, publication status, year of publication), 3) participants characteristics  
103 (mean age, severity of COVID-19 symptoms, dose of SARS-CoV-2 vaccine, SARS-CoV-2 lineage) and  
104 4) risk of bias. Disagreements were resolved by discussion or, if necessary, consultation with a  
105 third party.

### 106 *Outcome*

107 The primary endpoint of this reasearch was to measure the overall relative risk (RR) of any SARS-  
108 CoV-2 infection 14 days after the first dose (partially vaccinated), seven days after the second dose  
109 (fully vaccinated) and 14 days after at least one dose uptake.

110 As secondary endpoint, we aimed at measuring the risk of symptomatic infection following SARS-  
111 CoV-2 vaccination, and, if possible, quantifying the risk of hospitalization and death after partial  
112 and full vaccination protocol.

113 To this purpose, any COVID-19 infection, either symptomatic or asymptomatic, confirmed through  
114 PCR was considered as a COVID-19 case. Studies which did not declare to routinely perform a PCR  
115 test after vaccination were excluded. Documented SARS-CoV-2 infections (any positive rtPCR) at  
116 the baseline were excluded from the effectiveness analysis.

117 The risk of infection between vaccinated and unvaccinated groups was calculated as relative risk  
118 (RR). In order to quantify how much SARS-CoV-2 vaccination reduced the risk of infection relative  
119 to the control group, we computed the relative risk reduction (RRR), according to the formula  
120  $100 \times (1 - RR)$ .

#### 121 *SARS-CoV-2 infection episodes*

122 The primary analysis included the RR of any new positive infection episode among vaccinated and  
123 unvaccinated groups confirmed through PCR test. No restriction was imposed to PCR cycle  
124 threshold. The impact of SARS-CoV-2 vaccination on infection severity was investigated in  
125 secondary analysis as RR of symptomatic positive PCR, and possibly, RR of hospitalization and  
126 death following partial and full vaccination protocol. Both self-reported symptoms and symptoms  
127 ascertained through clinical visit were included.

128 Finally, COVID-19 episodes were classified as compatible with the B.1.1.7 variant and incompatible  
129 (i.e. B.135, non-B.1.1.7, unspecified).

130

#### 131 *Experimental group*

132 All adults eligible to undergo SARS-CoV-2 mass vaccination were included in the experimental  
133 group. BNT162b2 has been the first vaccine authorized for the emergency rollout, hence, more  
134 evidence on effectiveness was expected in the scientific literature. For the definition of case in the  
135 vaccinated groups we referred to Polack et al. Phase III RCT.[6] The same rules were applied to  
136 ChAdOx1/AZD1222 and mRNA-1273. Concerning ChAdOx1/AZD1222, only few studies on VE after  
137 the first dose administration were available, as the vaccine was approved later for the emergency  
138 rollout.[15] Ad26.COV2.S single dose administration was considered as full vaccination protocol,  
139 although the induction time lasts two weeks (Fig.1).[16, 47]

140 For each vaccine, the 14 days ensuing the first jab were considered as *induction time* for building  
141 COVID-19 immunogenicity, therefore, SARS-CoV-2 cases occurred within two weeks from the first  
142 dose were not included.[6, 17] In order to assess the effectiveness of full vaccination protocol, the  
143 upper follow-up limit was set at seven days after the second dose. (Fig.1) Only SARS-CoV-2 cases  
144 occurred at least one week after the second dose were attributed to the lack of vaccine  
145 protection.[6] Moreover, cases occurred within these seven days were still attributed to the first  
146 dose effectiveness (Fig.1).

147 VE against any positive SARS-COV-2 on at least one dose, was tested after 14 days from the first  
148 dose administration.

149 **FIGURE 1**

#### 150 *Control group*

151 In the general population, the mean incubation period for COVID-19 symptoms onset was  
152 estimated as 5.8 days.[18] Insofar, vaccination has been prioritized towards older and at-risk  
153 individuals and this aspect might bias the comparison with the unvaccinated cohort, which  
154 generally was younger and healthier. Overall, cohort studies drew the control group from the  
155 same population as the vaccinated group, while in few cases the cohort was the same community  
156 observed before-after the vaccination. For reasons mostly related to dearth of detailed  
157 information on unvaccinated individuals, the beginning of the follow-up for the control group was  
158 established at T0 (Fig.1).

#### 159 *Risk of bias*

160 In order to assess the risk of bias, we employed the Newcastle-Ottawa Scale (NOS) in cohort and  
161 case-control studies, and the NOS adapted for cross-sectional studies. For systematic review and  
162 meta-analysis, we used AMSTAR 2 checklist.[49]

#### 163 **Statistical analysis**

164 We performed a frequentist meta-analysis using the inverse variance (IV) method.[19] In addition,  
165 the Mantel-Haenszel (MH) method was applied because we expected to encounter sparse data,  
166 especially in estimating the RR of symptomatic cases after vaccination. The analysis was executed  
167 on R (version 4.0.5).

168 In the early phases of the mass vaccination campaign we expected the selected studies to be  
169 statistically heterogeneous. The main assumption underpinning the fixed effect model (FE) is that  
170 the true effect size is the same in all studies. This assumption was implausible in this systematic  
171 review, as the SARS-CoV-2 vaccination campaign has targeted priority population subgroups in the  
172 early stages. Therefore, the random effect (RE) meta-analysis was considered more appropriate to  
173 estimate the overall effect size. However, both FE and RE outputs were reported. In order to test  
174 for the overall heterogeneity both the Cochran's Q (chi-squared statistic) and I-squared values ( $I^2$ )  
175 were calculated. The Der Simonian and Laird method estimated the between studies variance  
176  $\tau^2$ . [20]

177 As the between-study heterogeneity can be caused by studies with extreme effect size, low quality  
178 or small sample size, the outliers test was implemented in order to detect which studies did not fit  
179 in the meta-analysis. Moreover, we explored the robustness of our meta-analyses results using  
180 influence analyses. [21] The Baujat Plot displayed which studies overly contributed to the  
181 heterogeneity, [22] while the leave-one-out analysis recomputed the pooled effect size and the  $I^2$   
182 with one study omitted at each step (Annex 3). The Graphic Display of Heterogeneity (GOSH) with  
183 Knapp-Hartung adjustment fits the meta-analysis model over all possible subsets of the included  
184 studies. [23] Three clustering algorithms detect potential patterns in the data distribution. GOSH  
185 analysis allows the identification of the studies that contribute to the overall heterogeneity and,  
186 possibly, to derive subgroup analysis therefrom (Annex 3). [20]

187 The subgroups meta-analysis was performed to identify further heterogeneity sources. [24] As we  
188 expected a limited number of studies in some subgroups ( $n < 10$ ), we opted for a FE model in  
189 subgroup meta-analysis. The subgroup levels were considered fixed and exhaustive. Nevertheless,  
190 RE and mixed model were added to the output, in order to catch discrepancies that might yield to  
191 inconclusive results (reported in Annex 4.1). In mixed model (or fixed plural model), subgroups are  
192 assumed to share a common estimate of the between-study heterogeneity. However, the general  
193 approach was to evaluate a separate  $\tau^2$  across subgroups when the number of studies was greater  
194 than five, because the estimate of  $\tau^2$  may be imprecise when the number of studies in a subgroup  
195 is smaller (i.e.  $n \leq 5$ ). [20, 25]

196 The subgroups meta-analysis enclosed vaccine type, quality, age of vaccinated population, and  
197 SARS-CoV-2 lineage detected through PCR tests. Although five or more studies were needed to

198 consistently achieve power from random effects meta-analysis, given a need for a conclusion, two  
199 studies were considered sufficient for the statistical inference.[26, 27]

200 In order to test whether publication biases have influenced the study conclusions we performed a  
201 funnel plot (Annex 4.2).[28]

## 202 **Results**

203 The web search provided 7,760 unduplicated records. Overall, 31 studies were selected for data  
204 extraction and qualitative data synthesis. (Fig. 5, Annex 2). There were 24 cohort studies, two  
205 case-control, one cross sectional, one matched observational, and three test negative case-  
206 control. Ten studies were performed in UK, eight in US, and five in Israel. RR of SARS-CoV-2  
207 infection among Health care workers (HCWs) was examined by 13 studies; four studies analysed  
208 long term care facilities (LCTF) residents and nine the general population. (Tab.3, Annex 2)

## 209 **Qualitative synthesis**

210 Four studies met the inclusion criteria for the systematic review but were not included in the  
211 quantitative analyses. [50, 53, 54, 55]

212 A study from Israel assessed the BNT162b2 effectiveness through national surveillance system.  
213 The study reported significant VE for asymptomatic SARS-CoV-2 infection (90.4%), symptomatic  
214 COVID-19 disease (96.3%), hospitalization (96.0%), severe and critical hospitalization (96.2%), and  
215 death (93.3%).[50]

216 Drury et al. conducted a study through the COVID Symptom Study app in UK. The results showed a  
217 progressive risk reduction for SARS-CoV-2 infections among vaccinated over time. Both BNT162b2  
218 (risk reduction increased from 58% to 72%) and ChAdOx1/AZD1222 (risk of infection increased  
219 from 39% to 60%) single dose effectiveness was tested against unvaccinated subjects.[53]

220 In a prospective cohort study conducted among frontline HCWs in US, Thompson et al. reported  
221 90% VE for full immunization and 80% for partial immunization.[54]

222 In a prospective cohort-study conducted on population registries in Scotland, Vasilieu et al.  
223 evaluated the effectiveness of BNT162b2 and ChAdOx1/AZD1222 single dose administration  
224 against COVID-19 hospitalization. VE was 85% for BNT162b and 94% for ChAdOx1 /AZD1222.[55]

## 225 **Meta-analysis**

226 In the following meta-analysis a RE model with inverse variance (IV) method was used throughout.  
227 The evidence synthesis was based on RR as measure of effect. Additionally, the FE estimates as



228 well as the Mantel-Haenszel outputs were reported in Table 1. The between-study variance  $\tau^2$  was  
229 computed for each RE meta-analysis.

230 Overall, 27 out of 31 studies were included in the meta-analysis. Despite some small sample sizes  
231 and few infection cases expected among vaccinated individuals, no study presented zero cells  
232 during the data extraction. ChAdOx1/AZD1222 effectiveness was investigated in 4 out of 27  
233 studies,[31, 32, 51, 52] while only one study estimated Ad26.COVID.S effectiveness.[47]

234 The Newcastle-Ottawa Quality Assessment Scale showed a satisfactory quality, with a median NOS  
235 score of six, a minimum of five and a maximum of eight.[29]

### 236 *RR of SARS-CoV-2 infection following vaccination*

237 The meta-analysis on first dose VE against any positive PCR pooled 17 studies and 22 entries.  
238 Jones' analysis spanned over a follow-up of two weeks (A) and, additionally, an extended period of  
239 six weeks (B).[30] Bernal et al. evaluated the effectiveness of one and two doses of BNT162b2  
240 vaccine on adults aged  $\geq 80$  years (A80 and B80) and  $\geq 70$  years (B70 and C70) in England.  
241 Additionally, the effectiveness of ChAdOx1/AZD1222 single dose (A70) and BNT162b2 one dose at  
242 least (C70) were tested on adults aged  $\geq 70$  years (A70).[31] Shetri et al. estimated the protective  
243 effects of BNT162b2 (A) and ChAdOx1/AZD1222 (B) first dose against any SARS-CoV-2  
244 infection.[32] One study from Denmark investigated BNT162b2 VE in two cohorts, namely long-  
245 term care facility residents (R) and HCWs (H).[33] Abu Raddad et al. measured the effectiveness of  
246 BNT162b2 against B.1.1.7 (A), B.1.351 (B), which became predominant within Qatar in the earliest  
247 2021, and any different (C) SARS-CoV-2 variants.[34] According to the RE meta-analysis results (IV),  
248 partially vaccinated showed a RRR=73% of any SARS-CoV-2 positive PCR compared to  
249 unvaccinated (RR=0.27). The FE model yielded lower effectiveness estimates after partial  
250 vaccination (RR=0.41; RRR=59%). Although both FE and RE (IV) showed a statistically significant  
251 result ( $p < 0.0001$ ), the heterogeneity was considerable ( $\tau^2=1.08$ ;  $H = 18.43$  [17.52; 19.38];  $I^2 =$   
252 99.7%); therefore the true size of the effect remained uncertain (Table 1, Fig.2a).

253 In the evaluation of the RR for any positive SARS-CoV-2 PCR following full vaccination protocol,  
254 only data on mRNA vaccines (BNT162b2 and mRNA-1273) were available. Sixteen studies and 17  
255 entries were included in this meta-analysis. One study evaluated Ad26.COVID.S effectiveness,  
256 whilst "Pritchard" indistinctly assessed the effectiveness of ChAdOx1/AZD1222 and BNT162b2  
257 after full vaccination protocol.[35] In "Abu Raddad" study, data on PCR test were available after

258 two weeks from the BNT162b2 second dose administration.[34] Four studies did not distinguish  
259 between BNT162b2 and mRNA-1273 vaccines.[36-39]

260 Basing on the RE meta-analysis results (IV), the RRR for any positive SARS-CoV-2 PCR following full  
261 vaccination protocol was 94% (95%CI=88%-98%) with RR=0.06 compared to unvaccinated  
262 individuals (Table 1, Fig.2b). FE yielded a RRR=88%. Although both FE and RE showed a statistically  
263 significant protective effect of full COVID-19 vaccination ( $p < 0.0001$ ), we should carefully draw  
264 conclusion over the true size effect because the heterogeneity was considerable ( $\tau^2=2.6$ ;  $H = 10.07$   
265 [9.22; 11.00];  $I^2=99.0\%$ ). The test for heterogeneity was significant at 1% ( $Q= 1621.96$ ,  $p=0$ ). (Table  
266 1, Fig.2b).

267 A longer follow-up period represented the main advantage of VE estimation after at least one  
268 dose uptake. The mean length of follow-up was indeed 54 days after the first dose administration.  
269 The meta-analysis on RR of testing positive for any SARS-CoV-2 PCR included 18 entries and 14  
270 studies. Menni et al. analysed the SARS-CoV-2 infection events on individuals who received one or  
271 two doses of BNT162b2 (A) and ChAdOx1/AZD1222 (B).[52] The results of RE meta-analysis (IV)  
272 produced a significant RRR=84% for vaccinated individuals compared to unvaccinated, with  
273 RR=0.26. The test for heterogeneity was significant at 1% ( $Q=1030.89$ ,  $p < 0.0001$ ). (Table 1, Fig.2c)

274 In order to assess the effectiveness of SARS-CoV-2 vaccination against symptomatic COVID-19  
275 infection, we performed two meta-analyses, in partially and fully vaccinated individuals (Table1).  
276 The meta-analysis on full vaccination protocol included only studies estimating VE among  
277 individuals aged <69 years. The meta-analyses on VE against symptomatic SARS-CoV-2 infection  
278 pooled 9 studies and 17 entries in total. In particular, nine and eight entries pertained to partial  
279 and full vaccination protocols respectively. The IV method displayed significant results for both FE  
280 and RE ( $p < 0.05$ ). According to the RE results (IV), partial vaccination achieved a RRR=78% (95%CI=  
281 31%-93%) for symptomatic SARS-CoV-2 infection compared to unvaccinated, while fully vaccinated  
282 subjects exhibited a RRR= 94% (95%CI=84%-98%) (Fig.3a, b). FE estimates of RRR were lower for  
283 both partially and fully vaccinated individuals (RRR=51% and RRR=76%, respectively). Both FE and  
284 RE were statistically significant ( $p < 0.05$ ).

285 Concerning hospitalization risk, a RE meta-analysis over 2 studies,[31, 40] produced a RR=0.38  
286 (95%CI=0.2719; 0.5242) after a full BNT162b2 vaccination protocol. ( $Q= 2.04$ ,  $p= 0.1529$ ;  $I^2 =$   
287 51.1% [0.0%; 87.6%]). Basing on Bernal et al. data, at least one dose of BNT162b2 vaccine ensured  
288 a RRR of death equal to 83%, compared to unvaccinated individuals.[31]

289 Considering the substantial heterogeneity and the significance of the heterogeneity test, we could  
 290 not be overly confident that the RR estimate would be robust in every context; therefore, we  
 291 performed a sensitivity analysis to address the between-study heterogeneity (Annex 3).

292

293 **Table 1)** Meta-analyses: relative risk of SARS-CoV-2 of positive PCR test after vaccination. Fixed  
 294 (FE) and Random Effect (RE), inverse variance method (IV) and Mantel-Haenszel (MH) method. RR  
 295 of any positive PCR and symptomatic positive PCR after SARS-CoV-2 vaccination. Any SARS-CoV-2  
 296 vaccination protocol.

Method	PCR test	SARS-CoV-2 vaccination protocol	N	Fixed effect model		Random effect model		$\tau^2$	I <sup>2</sup>
				RR [95%-CI]	p-value	RR [95%-CI]	p-value		
Inverse Variance (IV)	any positive PCR	Partially vaccinated	22	0.4115 [0.4025; 0.4207]	0	0.2657 [0.1710; 0.4127]	< 0.0001	1.0747 [0.6223; 3.0350]	99.70%
		Fully vaccinated	17	0.1204 [0.1120; 0.1295]	0	0.0586 [0.0266; 0.1292]	< 0.0001	1.6228 [1.0654; 2.4896]	99.00%
		At least one dose	18	0.3813 [0.3752; 0.3875]	0	0.1617 [0.1130; 0.2313]	< 0.0001	0.5862 [0.4444; 2.6714]	99.70%
	symptomatic positive PCR test	Partially vaccinated	9	0.4885 [0.4658; 0.5122]	< 0.0001	0.2181 [0.0685; 0.6944]	0.01	3.0607 [0.7297; 10.0860]	99.50%
		Fully vaccinated	8	0.2439 [0.2231; 0.2666]	< 0.0001	0.0629 [0.0245; 0.1613]	< 0.0001	1.7560 [1.1035; 14.6961]	98.80%
Mantel-Haenszel (MH)	any positive PCR	Partially vaccinated	22	0.2490 [0.2436; 0.2546]		0.2656 [0.1617; 0.4363]		1.374	
		Fully vaccinated	17	0.0447 [0.0419; 0.0477]		0.0586 [0.0228; 0.1505]		3.7986	
		At least one dose	18	0.3369 [0.3315; 0.3424]		0.1616 [0.1122; 0.2328]		0.6083	
	symptomatic positive PCR test	Partially vaccinated	9	0.2758 [0.2644; 0.2878]	0	0.2182 [0.0567; 0.8388]	0.0267	4.1669	99.60%
		Fully vaccinated	8	0.0811 [0.0752; 0.0874]	0	0.0626 [0.0167; 0.2344]	< 0.0001	3.5394	99.40%

297

298

FIGURE 2 a,b,c

299

300

FIGURE 3 a,b

301

302 *L' Abbé plot*

303 The L' Abbé plots in Fig.4 confirmed that, overall, infection events were in favour of the control  
 304 group (unvaccinated). Regarding the meta-analysis on any positive SARS-CoV-2 PCR case after  
 305 partial vaccination, no study laid above the 45° except "Dagan" and "Angel", which overlapped the  
 306 line of no-effect (Fig.4a), while "Dagan" contributed the most to the overall effect size.[11, 46]  
 307 Three studies clearly deviated from the effect-size line in Fig.4a,[34, 38, 41] and this might explain  
 308 the highest heterogeneity encountered in these data. Four studies were very small and less  
 309 precise.[38, 41-43] In fully vaccinated meta-analysis (Fig4b), "Pawloski" crossed the no-effect line,  
 310 while "Abu-Raddad B" and "Hall" evidently deviated from the dashed line of the pooled effect. In

311 Fig.4c “Hall” and “Lopez Bernal $\geq$ 80” diverged from the overall RE estimate (light dashed line),  
312 while “Monge” appeared as the largest sample sized.[31, 44]

313 Concerning symptomatic SARS-CoV-2 infections, the L’Abbè plots in Fig.4d) and 4e) confirmed that  
314 the infection rates were greater in unvaccinated groups than partially or fully vaccinated groups.  
315 Overall, “Dagan”, “Jones”, and “Abu-Raddad” were the largest sized studies (Fig.4d and 4e).[11,  
316 13, 45] In Fig.4d, “Dagan” partially overlapped the 45° line. No study frankly diverged from the  
317 light dashed line (RE overall RR) except “Hyams”.[11, 45]

318  FIGURE 4 a,b,c,d,e

### 319 *Subgroup meta-analysis*

320 The GOSH analysis did not indicate any clear cluster that contributed to the pooled imbalance  
321 (Annex 3). In the subgroup meta-analysis, we grouped the studies by type of vaccine, mean age of  
322 the sample ( $\geq$ 69 and  $<$  69 years), SARS-CoV-2 lineage, and bias assessment performed through  
323 Newcastle-Ottawa Scale (NOS). We classified NOS quality score into satisfactory (NOS  $\leq$ 6) and  
324 good (NOS  $>$ 6).[29] The meta-analysis was performed over two studies at least.[27] The results of  
325 FE model were presented in Tab.2 while mixed and RE subgroup meta-analyses were attached in  
326 Tab.10 and 11 (Appendix 4.1). The FE subgroup meta-analysis broadly explained the between-  
327 study heterogeneity because all subgroups produced a significant Q test ( $p <$  0.0001). However,  
328 considered the residual heterogeneity and the small number of studies in several subgroups,  
329 results must be interpreted with caution.

330 The first subgroup analysis compared different vaccine technologies. Basing on FE subgroup  
331 estimates, the RRR after BNT162b2 first dose ranged from 46% to 49% for any positive SARS-COV-  
332 2 PCR and from 35% to 32% for symptomatic events. The discrepancy might be explained by the  
333 low number of studies included in the subgroup evaluating VE against symptomatic SARS-COV-2  
334 infection (n=6) with respect to the group evaluating the effectiveness of BNT162b2 vaccine against  
335 any positive PCR (n=16) (Table 2). Only one study assessed the effectiveness of ChAdOx1/AZD1222  
336 against symptomatic PCR (RR=0.34), however, the effect size was probably overestimated.  
337 Corchado et al. analysis suggested a RRR=77% for Ad26.COV2.S,[47] while “Pritchard” did not  
338 distinguish between BNT162b2 and ChAdOx1/AZD1222 in VE analysis.[35] In FE the RR estimates  
339 were greater within high quality studies (NOS $>$ 6), either symptomatic or not (RR=0.12 and RR=0.07  
340 respectively) compared to satisfactory studies (NOS $\leq$ 6, RR=0.67 and RR=0.48, respectively). Partial  
341 vaccination effectiveness appeared lower within studies which examined older population ( $\geq$ 69

342 years) compared to younger, either on symptomatic PCR (RR= 0.40 and RR= 0.49, respectively) or  
 343 any positive PCR (RR=0.29 and RR= 0.48, respectively).

344 Regarding the FE subgroup meta-analysis in fully vaccinated (Table 2), BNT162b2 produced a  
 345 RRR=83% against any positive PCR and a RRR=68% against symptomatic SARS-CoV-2 infections.  
 346 The RE and the mixed model produced a RRR=94% against any positive PCR and RRR=84% against  
 347 symptomatic COVID-19. Further, the FE subgroup meta-analysis relative to the bias assessment  
 348 (NOS) showed a greater RR for low quality studies with respect to high quality studies (RR=0.01 in  
 349 symptomatic PCR and RR=0.33 in any positive PCR meta-analyses, respectively). Full vaccination  
 350 effectiveness against any positive PCR appeared slightly lower within studies which examined  
 351 older population ( $\geq 69$  years) compared to younger (RR=0.15 and RR= 0.12, respectively).

352 Concerning partial vaccination effectiveness against SARS-CoV-2 variants, the RRR of any positive  
 353 PCR for B.1.1.7 resulted nearly 60% in FE and 81% in mixed model. The RRR increased to 85% in FE  
 354 and 92% in mixed model after full vaccination. Although only “Abu Raddad” assessed the  
 355 effectiveness of BNT162b2 against B.1.351 lineage,[34] the RRR was lower for the B.1.351 variant  
 356 in both partially (RRR=9%) and fully vaccinated subjects (RRR=60%). Regarding symptomatic PCR,  
 357 the RRR within fully vaccinated individuals remained higher for B.1.1.7 (RRR=86%) with respect to  
 358 B.1.351 (RRR=64%) (Table 5a, b, e).

359 **Table 2)** Subgroup meta-analysis, any SARS-CoV-2 protocol. Fixed effect model.

Subgroups		N	Results for subgroups			Between-groups heterogeneity		
			RR [95%-CI]	I <sup>2</sup>	tau <sup>2</sup>	Q	df(Q)	p-value
<b>a) Partially vaccinated, any positive PCR - fixed effect</b>								
Vaccine	BNT162b2	16	0.5250[0.5123;0.5381]	99.60%	0.7549	3108.43	3	0
	ChAdOx1/AZD 1222	2	0.2277[0.2122;0.2443]	98.90%	0.3565			
	BNT162b2/mRNA-1273	3	0.2778[0.2474;0.3120]	98.80%	1.0692			
	BNT162b2/ChAdOx1/AZD 1222	1	0.0357[0.0323;0.0393]	--	--			
Quality	NOS $\leq 6$	15	0.4816[0.4704;0.4931]	99.60%	0.6113	1502.28	1	0
	NOS $> 6$	7	0.1219[0.1142;0.1302]	99.70%	3.3748			
Age	< 69 years	15	0.4828[0.4702;0.4958]	99.80%	1.5669	463.24		< 0.0001
	$\geq 69$ years	7	0.2845[0.2733;0.2962]	98.60%	0.2424			
Lineage	B.1.1.7	8	0.3903[0.3777;0.4033]	99.70%	0.9447	3031.61	3	0
	B.1.1.7/non B.1.1.7	5	0.1492[0.1418;0.1569]	99.70%	1.4303			
	not specified	8	0.3254[0.2971;0.3565]	97.10%	0.6506			
	B.1.351	1	0.9080[0.8717;0.9458]	--	--			
<b>b) Fully vaccinated, any positive PCR - fixed effect</b>								
Vaccine	BNT162b2	11	0.1680 [0.1537; 0.1836]	98.40%	1.7775	702.84	3	< 0.0001
	BNT162b2/mRNA-1273	4	0.1624 [0.1394; 0.1893]	98.90%	3.7392			
	BNT162b2/ChAdOx1/AZD1222	1	0.0062 [0.0049; 0.0078]	--	--			
	Ad26.COV2.S	1	0.2338 [0.0745; 0.7337]	--	--			
Quality	NOS $\leq 6$	11	0.1947 [0.1797; 0.2108]	98.50%	1.3935	827.35	1	< 0.0001
	NOS $> 6$	6	0.0112 [0.0094; 0.0134]	95.90%	1.6474			
Age	< 69 years	13	0.1171 [0.1084; 0.1266]	99.30%	3.0726	4.21	1	0.0403
	$\geq 69$ years	4	0.1487 [0.1200; 0.1843]	65.00%	0.2931			
Lineage	B.1.1.7	4	0.1448 [0.1231; 0.1703]	95.90%	0.817	1000.54	3	< 0.0001
	B.1.1.7/non B.1.1.7	5	0.0190 [0.0165; 0.0219]	98.60%	1.9969			

	not specified	7	0.1692 [0.1452; 0.1971]	97.70%	3.4732			
	B.1.351	1	0.4027 [0.3533; 0.4592]	--	--			
<b>c) At least one dose, any positive PCR - fixed effect</b>								
Vaccine	BNT162b2	12	0.2575 [0.2511; 0.2640]	99.60%	0.6218	2752.22	2	0
	BNT162b2/mRNA-1273	4	0.5641 [0.5517; 0.5767]	98.50%	0.4039			
	ChAdOx1/AZD 1222	2	0.1462 [0.1354; 0.1578]	83.10%	0.2114			
Quality	NOS ≤6	16	0.2550 [0.2491; 0.2610]	99.40%	0.432	2182.95	1	0
	NOS >6	2	0.5525 [0.5402; 0.5650]	99.90%	8.9219			
Age	< 69 years	12	0.2196 [0.2133; 0.2260]	99.30%	0.5076	2070.75	1	0
	≥ 69 years	6	0.4927 [0.4832; 0.5025]	99.80%	0.5585			
Lineage	B.1.1.7	4	0.3357 [0.3223; 0.3497]	99.80%	0.8863	1015.58	2	< 0.0001
	B.1.1.7/non B.1.1.7	5	0.1463 [0.1372; 0.1560]	95.00%	0.3366			
	not specified	9	0.4231 [0.4154; 0.4310]	99.80%	0.5975			
<b>d) Partially vaccinated, symptomatic positive PCR - fixed effect</b>								
Vaccine	BNT162b2	6	0.6572 [0.6245; 0.6915]	99.60%	1.1044	1414.28	3	< 0.0001
	ChAdOx1/AZD 1222	1	0.3441 [0.1763; 0.6715]	--	--			
	BNT162b2/mRNA-1273	1	0.5552 [0.4336; 0.7111]	--	--			
	BNT162b2/ChAdOx1/AZD 1222	1	0.0270 [0.0231; 0.0317]	--	--			
Quality	NOS ≤6	6	0.6688 [0.6354; 0.7039]	99.60%	0.7447	1057.05	1	< 0.0001
	NOS >6	3	0.0676 [0.0595; 0.0769]	99.50%	3.5694			
Age	< 69 years	7	0.4902 [0.4673; 0.5143]	99.60%	3.384	1.25	1	0.2636
	≥ 69 years	2	0.3962 [0.2736; 0.5737]	0.00%	--			
Lineage	B.1.1.7	3	0.2410 [0.1801; 0.3224]	89.10%	0.5695	26.49	3	< 0.0001
	B.1.1.7/non B.1.1.7	2	0.5032 [0.4789; 0.5287]	99.90%	5.242			
	not specified	4	0.4116 [0.3326; 0.5094]	94.10%	1.3278			
<b>e) Fully vaccinated, symptomatic positive PCR - fixed model</b>								
Vaccine	BNT162b2	6	0.3181 [0.2901; 0.3489]	94.90%	0.3245	488.27	2	< 0.0001
	BNT162b2/ChAdOx1/AZD1222	1	0.0021 [0.0012; 0.0036]	--	--			
	BNT162b2/mRNA-1273	1	0.0131 [0.0086; 0.0200]	--	--			
Quality	NOS ≤6	5	0.3301 [0.3008; 0.3622]	93.00%	0.1911	492.15	1	< 0.0001
	NOS >6	3	0.0085 [0.0063; 0.0116]	94.60%	1.4624			
Lineage	B.1.1.7	2	0.1347 [0.1034; 0.1753]	94.80%	1.565	222.39	3	< 0.0001
	B.1.1.7/non B.1.1.7	3	0.2744 [0.2408; 0.3127]	99.40%	6.8062			
	not specified	2	0.0166 [0.0111; 0.0248]	91.80%	2.5779			
	B.1.351	1	0.3598 [0.3111; 0.4162]	--	--			

360

361 *Publication bias*

362 The funnel plots were displayed in Fig.26 (Annex 4.2). The contour-enhanced funnel plots did not  
 363 exhibit publication bias. The majority of the studies fell into  $p < 0.01$  except "Tenforde" (Fig.26 a, d).

364 The Egger test indicated the presence of funnel plot asymmetry in meta-analysis for symptomatic  
 365 SARS-CoV-2 RR after full vaccination protocol (intercept=-11.271,  $p=0.026$ ), although it may lack  
 366 the statistical power to detect bias, because the number of studies was small ( $n < 10$ ).

## 367 DISCUSSION

368 Despite the considerable between-study heterogeneity, our findings provided evidence that any  
 369 COVID-19 vaccine is highly effective outside the controlled conditions of the clinical trials. Overall,  
 370 SARS-CoV-2 vaccination is effective in reducing the number of new COVID-19 events, either  
 371 asymptomatic or symptomatic, with the greatest benefit achieved after completing the full  
 372 vaccination protocol. Fewer real-world data were available for ChAdOx1/AZD1222 due to its later  
 373 regulatory approval. Yet, vaccination with ChAdOx1/AZD1222 resulted in the rare onset of

374 immune thrombotic thrombocytopenia; therefore, it underwent an additional careful monitoring  
375 process by European Union (EU) regulatory authorities.[48]

376 According to our findings, partially vaccinated individuals were only one-fourth as likely (RR=0.26)  
377 to develop any SARS-CoV-2 infection, as were unvaccinated individuals; whilst the overall risk of  
378 symptomatic infection was slightly lower (RR=0.22). The full vaccination schedule was effective at  
379 94% against asymptomatic and symptomatic positive PCR tests. Concerning hospitalization risk, a  
380 meta-analysis over two studies,[31, 40] yielded a RRR=62% ensuing a full BNT162b2 vaccination  
381 protocol. Concerning mortality risk, our findings corroborated Bernal et al. study,[31] conducted  
382 over 7.5 million adults aged 70 years and older in UK. At least one dose of BNT162b2 was  
383 approximately 83%, effective at preventing death compared to unvaccinated individuals, while  
384 there was insufficient follow-up to assess ChAdOx1/AZD1222 impact on mortality because of the  
385 later rollout.

386 The subgroup analysis did not find any significant difference in effectiveness between the mRNA  
387 and the modified adenovirus vaccines, in part because the evidence, especially for  
388 ChAdOx1/AZD1222, was still very scarce. Up to May 15, only two studies evaluated  
389 ChAdOx1/AZD1222,[31, 32, 51, 52] and only one Ad26.COVS effectiveness.[47] As expected,  
390 COVID-19 VE appeared higher in adults aged <69 years. The evaluation of VE against the SARS-  
391 CoV-2 variants remained a key point that lacked of robustness in results. In fact, only one study  
392 investigated the effectiveness of BNT162b2 against two variants of concern.[34] The RR of  
393 infection following a full vaccination protocol appeared larger for B.1.351 (South Africa) variant  
394 compared to B.1.1.7 (UK). Although the evidence suggested a lower VE against SARS-COV-2  
395 variants of concern, our findings were not sufficient to assert that COVID-19 full vaccination  
396 protocol is 60% effective against B.1.351 and 94% effective against B.1.1.7.

397 Our research aimed at addressing questions not answered by clinical trials, by including non-  
398 randomized studies undertaken after vaccine licensure. Moreover, we attempted to assess VE  
399 within different subgroups not included in the preauthorization vaccine clinical trials. Although  
400 imprecise, real world data confirmed the experimental evidence. Nevertheless, the lower level of  
401 protection assured against emerging variants of concern encouraged to pursue an accurate and  
402 robust VE validation.

403 This systematic review acknowledged several limitations. Undeniably, the expected heterogeneity  
404 stemmed from the observational design of the included studies. Unless a randomized process, it is

405 unlikely to be reduced in any circumstances. Moreover, several studies lacked of data on  
406 population characteristics. For instance, the meta-analysis predominantly included Caucasian  
407 populations whereas vaccines may have different effectiveness across individuals from different  
408 ethnicities. Moreover, five studies did not declare to test systematically the vaccinated cohort  
409 during the follow-up. The absence of active laboratory surveillance within vaccinated individuals  
410 might have resulted in an underestimation of asymptomatic cases. However, we did not consider a  
411 different rate of testing as a bias of concern in terms of RR estimate, because both vaccinated and  
412 unvaccinated individuals underwent the same case investigation and contact tracing protocol.  
413 Moreover, when systematic testing was not performed, asymptomatic testing was available to  
414 different extent: workplace exposures (HCWs), out-of-state travellers or per-request.[37] In  
415 general, SARS-CoV-2 PCR testing was highly accessible and free of charge.[11, 50]

416 However, asymptomatic cases which progressed into symptomatic disease could act as source of  
417 bias in both vaccinated and unvaccinated groups.[37, 43] Finally, public health mitigation  
418 measures might contribute to the underestimation of SARS-CoV-2 vaccine effectiveness.  
419 Unfortunately, the extent to which primary prevention restrictions affected VE was beyond the  
420 scope of this study.

421 By way of conclusion, we can state that significant reduction in RR of asymptomatic infection  
422 within partially vaccinated was not corroborated by sufficient statistical robustness for the  
423 generalizability of results. However, full vaccination effectiveness over symptomatic and  
424 asymptomatic SARS-CoV-2 infections risk, confirmed the RCTs results, except larger CI.

425 To the best of our knowledge, this is the first evidence-based data synthesis on SARS-CoV-2 VE.  
426 Our findings support the maximization of the full vaccination coverage and encourage a better  
427 calibration of the statistical inference as the mass vaccination wears on. Long-term vaccine  
428 effectiveness remains unexplained and needs further investigation. Better evidence over the  
429 impact of SARS-CoV-2 variants are vital in order to monitor mutations associated with vaccine  
430 escape.

431

#### 432 **AUTHOR AFFILIATIONS:**

433 1 Italia Ministero della Salute Direzione generale della prevenzione sanitaria  
434 Roma, Lazio, IT - Italian Ministry of Health, HQ, General Directorate of Prevention, Rome, Italy



435 2 IQVIA, London, 210 Pentonville Road N19JY, United Kingdom

436 **Corresponding author:**

437 Meggiolaro Angela, MD, MSc, PhD

438 Italian Ministry of Health, HQ

439 General Directorate of Prevention

440 Viale G.Ribotta, Rome (IT)

441 [a.meggiolaro@sanita.it](mailto:a.meggiolaro@sanita.it)

442

443 **FUNDING:** This work was supported by the Italian Ministry of Health.

444 **COMPETING INTERESTS:** none.

445 **ETHICS APPROVAL STATEMENT:** No ethics committee approval was required.

446 **CONTRIBUTORSHIP STATEMENT:** Each named author has substantially contributed to conducting  
447 the underlying research and writing the paper.

448 **DATA SHARING STATEMENT:** this manuscript does not contain personal and/or medical  
449 information about identifiable individuals. The study protocol is available at PROSPERO web  
450 registry (n. CRD42021240143). The statistical analysis plan is available upon request from the  
451 Authors.

452 **PATIENT AND PUBLIC INVOLEMENT:** patients were involved by primary studies.

453 **REFERENCES**

454 1. (<https://COVID19.who.int/> accessed 13.07.2021)

455 2. Chen Y, Liu Q, Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis.  
456 Journal of medical virology. 2020 Apr;92(4):418-23.

457 3. Peng Y, Mentzer AJ, Liu G, Yao X, Yin Z, Dong D, Dejnirattisai W, Rostron T, Supasa P, Liu C, Lopez-  
458 Camacho C. Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK  
459 convalescent individuals following COVID-19. Nature immunology. 2020 Nov;21(11):1336-45.

460 4. Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, Voysey M, Aley PK,  
461 Angus B, Babbage G, Belij-Rammerstorfer S. Safety and immunogenicity of ChAdOx1 nCoV-19  
462 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind,  
463 randomised, controlled, phase 2/3 trial. The Lancet. 2020 Dec 19;396(10267):1979-93.

464 5. (<https://www.ema.europa.eu/en/medicines> accessed 13.07.2021)

- 465 6. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Marc GP, Moreira ED,  
466 Zerbini C, Bailey R. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. *New England*  
467 *Journal of Medicine*. 2020 Dec 10.
- 468 7. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Roupheal N,  
469 Creech CB, McGettigan J. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. *New England*  
470 *Journal of Medicine*. 2021 Feb 4;384(5):403-16.
- 471 8. (<https://www.gavi.org/vaccineswork/what-difference-between-efficacy-and-effectiveness>;  
472 accessed 13.07.2021)
- 473 9. Aran D. Estimating real-world COVID-19 vaccine effectiveness in Israel using aggregated counts.  
474 *MedRxiv*. 2021 Jan 1.
- 475 10. Chodick G, Tene L, Patalone T, Gazit S, Ben-Tov A, Cohen D, Muhsen K. The Effectiveness of the First  
476 Dose of BNT162b2 Vaccine in Reducing SARS-CoV-2 Infection: Real-World Evidence. Available at  
477 SSRN 3769977. 2021 Jan 20.
- 478 11. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, Hernán MA, Lipsitch M, Reis B, Balicer  
479 RD. BNT162b2 mRNA COVID-19 vaccine in a nationwide mass vaccination setting. *New England*  
480 *Journal of Medicine*. 2021 Apr 15;384(15):1412-23.
- 481 12. Rossman, H. et al. Patterns of COVID-19 pandemic dynamics following deployment of a broad  
482 national immunization program. (2021) doi: 10.1101/2021.02.08.21251325 .
- 483 13. Jones NK, Rivett L, Seaman S, Samworth RJ, Warne B, Workman C, Ferris M, Wright J, Quinnell N,  
484 Shaw A, Goodfellow IG. Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2  
485 infection. *Elife*. 2021 Apr 8;10:e68808.
- 486 14. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ,  
487 Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of  
488 studies that evaluate health care interventions: explanation and elaboration. *Journal of clinical*  
489 *epidemiology*. 2009 Oct 1;62(10):e1-34.
- 490 15. Voysey M, Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL,  
491 Bhorat QE, Bibi S. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-  
492 CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.  
493 *The Lancet*. 2021 Jan 9;397(10269):99-111.
- 494 16. Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, Goepfert PA, Truyers C,  
495 Fennema H, Spiessens B, Offergeld K. Safety and efficacy of single-dose Ad26. COV2. S vaccine  
496 against COVID-19. *New England Journal of Medicine*. 2021 Jun 10;384(23):2187-201.
- 497 17. Rothman KJ, Greenland S, Lash TL. *Modern epidemiology*. Philadelphia: Wolters Kluwer  
498 Health/Lippincott Williams & Wilkins; 2008 Sep 20.

- 499 18. McAloon C, Collins Á, Hunt K, Barber A, Byrne AW, Butler F, Casey M, Griffin J, Lane E, McEvoy D,  
500 Wall P. Incubation period of COVID-19: a rapid systematic review and meta-analysis of  
501 observational research. *BMJ open*. 2020 Aug 1;10(8):e039652.
- 502 19. Fleiss JL, Gross AJ. Meta-analysis in epidemiology, with special reference to studies of the  
503 association between exposure to environmental tobacco smoke and lung cancer: a critique. *Journal*  
504 *of clinical epidemiology*. 1991 Jan 1;44(2):127-39.
- 505 20. Schwarzer G, Carpenter JR, Rücker G. *Meta-analysis with R*. Cham: springer; 2015 Oct 8.
- 506 21. Viechtbauer W, Cheung MW. Outlier and influence diagnostics for meta-analysis. *Research*  
507 *synthesis methods*. 2010 Apr;1(2):112-25.
- 508 22. Baujat B, Mahé C, Pignon JP, Hill C. A graphical method for exploring heterogeneity in  
509 meta-analyses: application to a meta-analysis of 65 trials. *Statistics in medicine*. 2002 Sep  
510 30;21(18):2641-52.
- 511 23. Olkin I, Dahabreh IJ, Trikalinos TA. GOSH—a graphical display of study heterogeneity. *Research*  
512 *synthesis methods*. 2012 Sep;3(3):214-23.
- 513 24. Higgins JP, Thompson SG. Controlling the risk of spurious findings from meta-regression. *Statistics*  
514 *in medicine*. 2004 Jun 15;23(11):1663-82.
- 515 25. Borenstein M, Hedges LV, Higgins JP, Rothstein HR. A basic introduction to fixed-effect and  
516 random-effects models for meta-analysis. *Research synthesis methods*. 2010 Apr;1(2):97-111.
- 517 26. Jackson D, Turner R. Power analysis for random-effects meta-analysis. *Research synthesis methods*.  
518 2017 Sep;8(3):290-302.
- 519 27. Valentine JC, Pigott TD, Rothstein HR. " How many studies do you need? A primer on statistical  
520 power for meta-analysis": Erratum.
- 521 28. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical  
522 test. *Bmj*. 1997 Sep 13;315(7109):629-34.
- 523 29. Peterson J, Welch V, Losos M, Tugwell PJ. The Newcastle-Ottawa scale (NOS) for assessing the  
524 quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute.  
525 2011:1-2.
- 526 30. Jones NK, Rivett L, Seaman S, Samworth RJ, Warne B, Workman C, Ferris M, Wright J, Quinnell N,  
527 Shaw A, Goodfellow IG. Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2  
528 infection. *Elife*. 2021 Apr 8;10:e68808.
- 529 31. Bernal JL, Andrews N, Gower C, Stowe J, Robertson C, Tessier E, Simmons R, Cottrell S, Robertson R,  
530 O'Doherty M, Brown K. Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine  
531 and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalizations and mortality in  
532 older adults in England. *MedRxiv*. 2021 Jan 1.

- 533 32. Shrotri M, Krutikov M, Palmer T, Giddings R, Azmi B, Subbarao S, Fuller C, Irwin-Singer A, Davies D,  
534 Tut G, Bernal JL. Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against  
535 SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective  
536 cohort study. *The Lancet Infectious Diseases*. 2021 Jun 23.
- 537 33. Moustsen-Helms IR, Emborg HD, Nielsen J, Nielsen KF, Krause TG, Molbak K, Moeller KL, Berthelsen  
538 AS, Valentiner-Branth P. Vaccine effectiveness after 1st and 2nd dose of the BNT162b2 mRNA  
539 COVID-19 Vaccine in long-term care facility residents and healthcare workers—a Danish cohort  
540 study. *MedRxiv*. 2021 Jan 1.
- 541 34. Abu-Raddad LJ, Chemaitelly H, Butt AA. Effectiveness of the BNT162b2 COVID-19 Vaccine against  
542 the B. 1.1. 7 and B. 1.351 Variants. *New England Journal of Medicine*. 2021 May 5.
- 543 35. Pritchard E, Matthews PC, Stoesser N, Eyre DW, Gethings O, Vihta KD, Jones J, House T,  
544 VanSteenHouse H, Bell I, Bell JI. Impact of vaccination on new SARS-CoV-2 infections in the UK.  
545 *medRxiv*. 2021 Jan 1.
- 546 36. Mody A. Review 1: " FDA-authorized COVID-19 vaccines are effective per real-world evidence  
547 synthesized across a multi-state health system ". *Rapid Reviews COVID-19*. 2021 Apr 26.
- 548 37. Bouton TC, Lodi S, Turcinovic J, Weber SE, Quinn E, Korn C, Steiner J, Schechter-Perkins EM, Duffy E,  
549 Ragan EJ, Taylor BP. COVID-19 vaccine impact on rates of SARS-CoV-2 cases and post vaccination  
550 strain sequences among healthcare workers at an urban academic medical center: a prospective  
551 cohort study. *medRxiv*. 2021 Jan 1.
- 552 38. Tenforde MW. Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among  
553 Hospitalized Adults Aged  $\geq 65$  Years—United States, January–March 2021. *MMWR. Morbidity and*  
554 *mortality weekly report*. 2021;70.
- 555 39. Swift MD, Breeher LE, Tande AJ, Tommaso CP, Hainy CM, Chu H, Murad MH, Berbari EF, Virk A.  
556 Effectiveness of mRNA COVID-19 vaccines against SARS-CoV-2 infection in a cohort of healthcare  
557 personnel. *Clinical Infectious Diseases*. 2021 Apr 26.
- 558 40. Mason TF, Whitston M, Hodgson J, Watkinson RE, Lau YS, Abdulrazeg O, Sutton M. Effects of  
559 BNT162b2 mRNA vaccine on COVID-19 infection and hospitalization among older people: matched  
560 case control study for England. *medRxiv*. 2021 Jan 1.
- 561 41. Gras-Valentí P, Chico-Sánchez P, Algado-Sellés N, Jiménez-Sepúlveda NJ, Gómez-Sotero IL, Fuster-  
562 Pérez M, Cartagena-Llopis L, Sánchez-Valero M, Cerezo-Milán P, Martínez-Tornero I, Tremiño-  
563 Sánchez L. Effectiveness of the first dose of BNT162b2 vaccine to preventing COVID-19 in  
564 healthcare personnel. *Revista Espanola de Salud Publica*. 2021 Apr 29;95.
- 565 42. Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A, Wellington E, Stowe J, Gillson N, Atti A,  
566 Islam J. COVID-19 vaccine coverage in health-care workers in England and effectiveness of

- 567 BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. The  
568 Lancet. 2021 May 8;397(10286):1725-35.
- 569 43. Britton A, Slifka KM, Edens C, Nanduri SA, Bart SM, Shang N, Harizaj A, Armstrong J, Xu K, Ehrlich  
570 HY, Soda E. Effectiveness of the Pfizer-BioNTech COVID-19 vaccine among residents of two skilled  
571 nursing facilities experiencing COVID-19 outbreaks—Connecticut, December 2020–February 2021.  
572 Morbidity and Mortality Weekly Report. 2021 Mar 19;70(11):396.
- 573 44. Monge S, Olmedo C, Alejos B, Lapena M, Sierra MJ, Limia A. Direct and indirect effectiveness of  
574 mRNA vaccination against SARS-CoV-2 infection in long-term care facilities in Spain. medRxiv. 2021  
575 Jan 1.
- 576 45. Hyams C, Marlow R, Maseko Z, King J, Ward L, Fox K, Heath R, Turner A, Friedrich Z, Morrison L,  
577 Ruffino G. Assessing the effectiveness of BNT162b2 and ChAdOx1nCoV-19 COVID-19 vaccination in  
578 prevention of hospitalizations in elderly and frail adults: a single centre test negative case-control  
579 study.
- 580 46. Angel Y, Spitzer A, Henig O, Saiag E, Sprecher E, Padova H, Ben-Ami R. Association between  
581 vaccination with BNT162b2 and incidence of symptomatic and asymptomatic SARS-CoV-2 infections  
582 among health care workers. JAMA. 2021 May 6.
- 583 47. Corchado-Garcia J, Hughes T, Cristea-Platon T, Lenehan P, Pawlowski C, Bade S, O'Horo JC, Gores  
584 GJ, Williams AW, Badley AD, Halamka J. Real-world effectiveness of Ad26. COV2. S adenoviral  
585 vector vaccine for COVID-19.
- 586 48. COVID EA. Vaccine: EMA Finds Possible Link to very Rare Cases of Unusual Blood Clots with Low  
587 Blood Platelets.
- 588 49. Ma LL, Wang YY, Yang ZH, Huang D, Weng H, Zeng XT. Methodological quality (risk of bias)  
589 assessment tools for primary and secondary medical studies: what are they and which is better?.  
590 Military Medical Research. 2020 Dec;7(1):1-1.
- 591 50. Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, Brooks N, Smaja M, Mircus G, Pan K,  
592 Southern J. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and  
593 COVID-19 cases, hospitalizations, and deaths following a nationwide vaccination campaign in Israel:  
594 an observational study using national surveillance data. The Lancet. 2021 May 15;397(10287):1819-  
595 29.
- 596 51. Lumley SF, Rodger G, Constantinides B, Sanderson N, Chau KK, Street TL, O'Donnell D, Howarth A,  
597 Hatch SB, Marsden BD, Cox S. An observational cohort study on the incidence of SARS-CoV-2  
598 infection and B. 1.1. 7 variant infection in healthcare workers by antibody and vaccination status.  
599 medRxiv. 2021 Jan 1.
- 600 52. Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, Sudre CH, Nguyen LH, Drew DA, Merino J,  
601 Hu C. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID

602 Symptom Study app in the UK: a prospective observational study. *The Lancet Infectious Diseases*.  
603 2021 Apr 27.

604 53. Drury RE, O'Connor D. Symptom study app provides real-world data on COVID-19 vaccines. *Lancet*  
605 *Infect Dis*. 2021 Jul;21(7):890-891. doi: 10.1016/S1473-3099(21)00264-4. Epub 2021 Apr 27. PMID:  
606 33930321; PMCID: PMC8078875.

607 54. Thompson MG, Burgess JL, Naleway AL, Tyner HL, Yoon SK, Meece J, Olsho LEW, Caban-Martinez  
608 AJ, Fowlkes A, Lutrick K, Kuntz JL, Dunnigan K, Odean MJ, Hegmann KT, Stefanski E, Edwards LJ,  
609 Schaefer-Solle N, Grant L, Ellingson K, Groom HC, Zunie T, Thiese MS, Ivacic L, Wesley MG,  
610 Lamberte JM, Sun X, Smith ME, Phillips AL, Groover KD, Yoo YM, Gerald J, Brown RT, Herring MK,  
611 Joseph G, Beitel S, Morrill TC, Mak J, Rivers P, Harris KM, Hunt DR, Arvay ML, Kutty P, Fry AM,  
612 Gaglani M. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19  
613 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and  
614 Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021. *MMWR*  
615 *Morb Mortal Wkly Rep*. 2021 Apr 2;70(13):495-500. doi: 10.15585/mmwr.mm7013e3. PMID:  
616 33793460; PMCID: PMC8022879.

617 55. Vasileiou E, Simpson CR, Shi T, Kerr S, Agrawal U, Akbari A, Bedston S, Beggs J, Bradley D, Chuter A,  
618 de Lusignan S, Docherty AB, Ford D, Hobbs FR, Joy M, Katikireddi SV, Marple J, McCowan C, McGagh  
619 D, McMenamin J, Moore E, Murray JL, Pan J, Ritchie L, Shah SA, Stock S, Torabi F, Tsang RS, Wood R,  
620 Woolhouse M, Robertson C, Sheikh A. Interim findings from first-dose mass COVID-19 vaccination  
621 roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. *Lancet*.  
622 2021 May 1;397(10285):1646-1657. doi: 10.1016/S0140-6736(21)00677-2. Epub 2021 Apr 23.  
623 PMID: 33901420; PMCID: PMC8064669.

624

625

626 **Web appendix:** Supplementary material




627

**Figure 1)** Experimental group follow-up: the dashed line represents the *induction time* for the first and the second vaccine doses respectively. The solid line underpins the follow-up period.



All rights reserved. No reuse allowed without permission.

- 1 **Figure 2)** Forest plot, partially vaccinated. Any positive SARS-CoV-2 PCR RR [95%-CI]  $\geq 14$  days from  
 2 first dose uptake (a). Forest plot, fully vaccinated. Any positive PCR RR [95%-CI]  $\geq 7$  days from full  
 3 vaccination (b). Forest plot, any positive PCR RR [95%-CI],  $\geq 14$  days from vaccination with at least  
 4 one dose. IV method (c).






medRxiv preprint doi: <https://doi.org/10.1101/2021.08.25.21262529>; this version posted August 28, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.


All rights reserved. No reuse allowed without permission.

**Figure 3)** Forest plot, symptomatic positive SARS-CoV-2 PCR RR [95%-CI]  $\geq 14$  days from first dose uptake (a). Forest plot, fully vaccinated. Symptomatic positive PCR RR [95%-CI]  $\geq 7$  days from full vaccination (b). IV method.

a) Partially vaccinated, symptomatic positive PCR



b) Fully vaccinated, symptomatic positive PCR



medRxiv preprint doi: <https://doi.org/10.1101/2021.08.25.21262529>; this version posted August 28, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

**Fig.4) L'Abbè plots.** Partially vaccinated, any positive SARS-CoV-2 PCR RR  $\geq 14$  days from first SARS-CoV-2 dose administration (a). Fully vaccinated, any positive PCR RR,  $\geq 7$  days from full vaccination (b). At least one dose, any positive PCR RR  $\geq 14$  days from vaccination with first dose (c). Partially vaccinated, symptomatic positive PCR RR  $\geq 14$  days from first dose administration (d). Fully vaccinated, symptomatic positive SARS-CoV-2 PCR RR  $\geq 7$  days from full vaccination (e). The sizes of the plotted circles are proportional to the precision of the studies. The dashed lines marked the overall estimate of the log risk for RE (light) and FE (bold). The further the circle from the line of no effect, the greater the difference of event rates between intervention and control arms.

